Can-Fite Biopharma (NYSE-MKT: CANF)

Tiny float, bottomed over sold chart, at/near 52 week lows and on the verge of biotech breakthrough. This one could move fast this week with such a low share structure and perfect chart setup.

Can-Fite Biopharma (NYSE-MKT: CANF)

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company’s CF101 is in Phase II/III trials for the treatment of psoriasis and just completed successful Phase II trials for rheumatoid arthritis. Can-Fite’s liver cancer drug CF102 Phase II trial will start enrolling patients shortly. CF102 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and is approved for Compassionate Use by Israel’s Ministry of Health. The Company’s drug candidates have an excellent safety profile with experience in over 1,200 patients in clinical studies to date. The Company’s intellectual property portfolio consists of 150 patents issued and pending.

(NYSE-MKT: CANF) Highlights

Nothing but the facts: http:// http://smallcapir.com/wp-content/uploads/2014/11/2014-11-04-CANF-FactSheet_FINAL1.pdf

Power Point Presentation: http://smallcapir.com/wp-content/uploads/2014/11/11-7-2014-Can-Fite-Presentation-BR_FINAL0001-1.pdf

Older Analysis by Roth Capital with $15 price target, prior to the up list to the NYSE: http://smallcapir.com/wp-content/uploads/2014/11/ROTH-Capital-Analysis-1.pdf

This should get everyone in our group familiar with Can-Fite Biopharma for now.
Please share this article